Simplify Logo

Full-Time

Manager of Accounting AND Sec Reporting

Confirmed live in the last 24 hours

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops genetically modified T cells for cancer

Hardware
Biotechnology
Healthcare

Compensation Overview

$120k - $165kAnnually

+ Annual Cash Bonus + Long-term Incentives + Employee Stock Purchase Plan

Senior

San Carlos, CA, USA

Category
Financial Accounting
Accounting
Requirements
  • Bachelor’s degree in accounting or finance, CPA preferred
  • Minimum of 7 years of experience including a mix of public accounting and public biotech/pharma industry experience
  • In-depth knowledge of US GAAP, SEC reporting and SOX 404 compliance
  • Hands on experience with Active Disclosure preferred
  • Previous experience with payroll processing
  • High degree of accuracy and attention to detail
  • Organized and able to manage multiple projects while exemplifying stellar interpersonal skills
  • Excellent communication skills (written and oral)
  • Proficient with Microsoft Office (Outlook, Word, Excel, Powerpoint)
  • Experience with Dynamics Business Central
  • Results and goal-oriented mindset with an opportunistic eye towards process improvements
  • Strong ability to prioritize and organize work. Have the agility to adjust quickly to new priorities
  • Must be able to collaborate and communicate effectively
Responsibilities
  • Assist in the preparation of SEC filings and supporting documents
  • Assist in the preparation of quarterly consolidated financials
  • Participate in monthly close process
  • Prepare and book journal entries for month-end close
  • Interact with Accounting team members
  • Collaborate with third-party consulting firm for stock-based compensation expense
  • Back up payroll including prepare and processing payroll
  • Assist with other payroll tasks as needed
  • Maintain and update SOX documentation and audit schedules
  • Special projects as requested

Adicet Bio, Inc. is a pioneering biotechnology company focused on the development of innovative gamma delta T cell therapies for cancer. This firm's work in advancing genetically modified T cells that selectively target tumors with chimeric antigen receptors and T cell receptor-like antibodies positions it as a leader in oncology treatment advancements. The dedication to enhancing tumor targeting and improving treatment persistence underscores a strong commitment to patient care and scientific excellence, making it a distinguished workplace for professionals passionate about making significant impacts in cancer treatment.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-4%

1 year growth

1%

2 year growth

44%